AU2002221316A1 - Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament - Google Patents
Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicamentInfo
- Publication number
- AU2002221316A1 AU2002221316A1 AU2002221316A AU2131602A AU2002221316A1 AU 2002221316 A1 AU2002221316 A1 AU 2002221316A1 AU 2002221316 A AU2002221316 A AU 2002221316A AU 2131602 A AU2131602 A AU 2131602A AU 2002221316 A1 AU2002221316 A1 AU 2002221316A1
- Authority
- AU
- Australia
- Prior art keywords
- pro
- gly
- arg
- fibrin
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title 1
- 102000009123 Fibrin Human genes 0.000 abstract 4
- 108010073385 Fibrin Proteins 0.000 abstract 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 4
- 229950003499 fibrin Drugs 0.000 abstract 4
- 230000005764 inhibitory process Effects 0.000 abstract 3
- 235000018102 proteins Nutrition 0.000 abstract 3
- 150000001408 amides Chemical class 0.000 abstract 2
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Peptides or proteins (I), based on the alpha - and beta -chain sequences of fibrin/fibrinogen, or their salts, amides and/or mixtures with each other or other materials, have therapeutic and/or preventive use in human or veterinary medicine. Peptides or proteins of formula R 1R 2N-CH 2-C(O)-Z 1-Z 2 (I), or their salts, amides and/or mixtures with each other or other materials, have therapeutic and/or preventive use in human or veterinary medicine. R 1, R 2H or up to 10C saturated or unsaturated hydrocarbyl; Z 1histidine or proline residue; and Z 2arginine residue or a peptide or protein residue (preferably of 2-30 aminoacids) having an initial arginine residue. An independent claim is included for medicaments containing (I). ACTIVITY : Antiinflammatory; antibacterial; immunosuppressive; Antirheumatic; Antiarteriosclerotic; vasotropic; Thrombolytic; anticoagulant; cytostatic; antipsoriatic. In tests for inhibition of reperfusion damage after surgically induced ischemia in rat cardiac tissue, intravenous administration of Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala-Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg (Ia) at 800 Microg/kg reduced the precentage of dead tissue from 46% to 29%. MECHANISM OF ACTION : Fibrin antagonist; inhibition of fibrin-mediated adhesion of cells from the blood-stream onto vascular endothelium and/or migration of such cells into tissue; inhibition of deposition and adhesion of fibrin cleavage fragments on vascular walls.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT2063/2000 | 2000-12-12 | ||
| AT20632000 | 2000-12-12 | ||
| PCT/AT2001/000387 WO2002048180A2 (en) | 2000-12-12 | 2001-12-07 | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002221316A1 true AU2002221316A1 (en) | 2002-06-24 |
Family
ID=3689750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002221316A Abandoned AU2002221316A1 (en) | 2000-12-12 | 2001-12-07 | Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7271144B2 (en) |
| EP (2) | EP1586586B1 (en) |
| JP (1) | JP4181874B2 (en) |
| KR (1) | KR100864069B1 (en) |
| CN (2) | CN1518558B (en) |
| AT (2) | ATE425184T1 (en) |
| AU (1) | AU2002221316A1 (en) |
| BG (1) | BG107891A (en) |
| BR (1) | BR0116122A (en) |
| CA (1) | CA2430972C (en) |
| CY (2) | CY1106108T1 (en) |
| CZ (1) | CZ20031630A3 (en) |
| DE (2) | DE50110182D1 (en) |
| DK (2) | DK1341819T3 (en) |
| EA (1) | EA005576B1 (en) |
| EE (1) | EE200300283A (en) |
| ES (2) | ES2323963T3 (en) |
| HK (1) | HK1084400A1 (en) |
| HR (1) | HRP20030564A2 (en) |
| HU (1) | HUP0401536A3 (en) |
| IL (2) | IL156360A0 (en) |
| MX (1) | MXPA03005218A (en) |
| NO (1) | NO330767B1 (en) |
| NZ (1) | NZ550619A (en) |
| PL (2) | PL209752B1 (en) |
| PT (2) | PT1586586E (en) |
| SI (2) | SI1341819T1 (en) |
| SK (1) | SK7062003A3 (en) |
| WO (1) | WO2002048180A2 (en) |
| YU (1) | YU53803A (en) |
| ZA (1) | ZA200304545B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1518558B (en) | 2000-12-12 | 2010-06-16 | 菲布雷克斯医疗研究及开发有限责任公司 | Peptides and/or proteins and use thereof for production of therapeutic and/or prophylactic medicament |
| AU2005256121B2 (en) * | 2004-06-25 | 2011-03-03 | Fibrex Medical Research & Development Gmbh | Use of peptides derived from the A alpha or B beta chain of human fibrinogen for the treatment of shock |
| FR2879604B1 (en) * | 2004-12-22 | 2010-08-13 | Biomerieux Sa | FIBRIN-DERIVED CITRULIN PEPTIDES RECOGNIZED BY RHE-PATIENT-SPECIFIC AUTO-ANTIBODIES AND USES THEREOF |
| AT502987A1 (en) | 2005-12-23 | 2007-07-15 | Fibrex Medical Res & Dev Gmbh | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEMORRHAGIC SHOCK AND ITS AFFILIATES |
| WO2007095659A1 (en) * | 2006-02-23 | 2007-08-30 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives, preparation thereof and the use thereof for preparing a therapeutic and/or preventative medicament |
| US20110098442A1 (en) * | 2006-02-23 | 2011-04-28 | Fibrex Medical Research & Development Gmbh | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| DE602007002553D1 (en) * | 2006-02-23 | 2009-11-05 | Fibrex Medical Res & Dev Gmbh | THEIR USE FOR THE PREPARATION OF A THERAPEUTIC AND / OR PROPHYLACTICALLY ACTIVE PHARMACEUTICAL COMPOSITION |
| FR2900657B1 (en) | 2006-05-03 | 2009-04-17 | Univ Toulouse | IDENTIFICATION OF MACROPHAGE ACTIVATION MODULATORS, USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| WO2009038729A2 (en) | 2007-09-17 | 2009-03-26 | Regenerx Biopharmaceuticals, Inc. | Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen |
| FR2908134B1 (en) * | 2007-12-04 | 2012-10-12 | Univ Toulouse 3 Paul Sabatier | IDENTIFICATION OF MACROPHAGE ACTIVATION MODULATORS, USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
| JP5410997B2 (en) * | 2008-01-31 | 2014-02-05 | 則行 川村 | Depression and depression markers and detection / diagnosis using them |
| US20090286725A1 (en) * | 2008-05-15 | 2009-11-19 | Fibrex Medical Research & Development Gmbh | Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| US8088890B2 (en) | 2008-09-26 | 2012-01-03 | Fibrex Medical Research & Development Gmbh | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| WO2010043444A2 (en) * | 2008-10-15 | 2010-04-22 | Fibrex Medical Research & Development Gmbh | Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof |
| US20100152832A1 (en) * | 2008-12-12 | 2010-06-17 | Medtronic Vascular, Inc. | Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927916A (en) * | 1984-04-23 | 1990-05-22 | The General Hospital Corporation | Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides |
| US5965107A (en) * | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| DE19729591A1 (en) * | 1997-07-10 | 1999-02-11 | Therasorb Medizinische Systeme | Agents for the treatment and / or prophylaxis of microcirculation disorders |
| FR2795735B1 (en) * | 1999-07-01 | 2001-09-07 | Univ Toulouse | CITRULLIN FIBRIN DERIVATIVES AND THEIR USE FOR DIAGNOSIS OR TREATMENT OF RHUMATOID POLYARTHRITIS |
| CN1518558B (en) * | 2000-12-12 | 2010-06-16 | 菲布雷克斯医疗研究及开发有限责任公司 | Peptides and/or proteins and use thereof for production of therapeutic and/or prophylactic medicament |
| US7201763B2 (en) | 2001-10-24 | 2007-04-10 | Boston Scientific Scimed, Inc. | Distal balloon waist material relief and method of manufacture |
-
2001
- 2001-12-07 CN CN018225993A patent/CN1518558B/en not_active Expired - Fee Related
- 2001-12-07 EA EA200300678A patent/EA005576B1/en not_active IP Right Cessation
- 2001-12-07 BR BR0116122-9A patent/BR0116122A/en not_active Application Discontinuation
- 2001-12-07 PT PT05012488T patent/PT1586586E/en unknown
- 2001-12-07 EP EP05012488A patent/EP1586586B1/en not_active Expired - Lifetime
- 2001-12-07 HU HU0401536A patent/HUP0401536A3/en unknown
- 2001-12-07 KR KR1020037007799A patent/KR100864069B1/en not_active IP Right Cessation
- 2001-12-07 DK DK01270546T patent/DK1341819T3/en active
- 2001-12-07 DE DE50110182T patent/DE50110182D1/en not_active Expired - Lifetime
- 2001-12-07 WO PCT/AT2001/000387 patent/WO2002048180A2/en active IP Right Grant
- 2001-12-07 AT AT05012488T patent/ATE425184T1/en active
- 2001-12-07 PL PL390342A patent/PL209752B1/en not_active IP Right Cessation
- 2001-12-07 EE EEP200300283A patent/EE200300283A/en unknown
- 2001-12-07 PT PT01270546T patent/PT1341819E/en unknown
- 2001-12-07 YU YU53803A patent/YU53803A/en unknown
- 2001-12-07 CA CA2430972A patent/CA2430972C/en not_active Expired - Fee Related
- 2001-12-07 IL IL15636001A patent/IL156360A0/en unknown
- 2001-12-07 DK DK05012488T patent/DK1586586T3/en active
- 2001-12-07 NZ NZ550619A patent/NZ550619A/en unknown
- 2001-12-07 EP EP01270546A patent/EP1341819B1/en not_active Expired - Lifetime
- 2001-12-07 SI SI200130609T patent/SI1341819T1/en unknown
- 2001-12-07 ES ES05012488T patent/ES2323963T3/en not_active Expired - Lifetime
- 2001-12-07 DE DE50114771T patent/DE50114771D1/en not_active Expired - Lifetime
- 2001-12-07 PL PL362924A patent/PL209419B1/en not_active IP Right Cessation
- 2001-12-07 JP JP2002549711A patent/JP4181874B2/en not_active Expired - Fee Related
- 2001-12-07 SI SI200130917T patent/SI1586586T1/en unknown
- 2001-12-07 AU AU2002221316A patent/AU2002221316A1/en not_active Abandoned
- 2001-12-07 MX MXPA03005218A patent/MXPA03005218A/en active IP Right Grant
- 2001-12-07 CZ CZ20031630A patent/CZ20031630A3/en unknown
- 2001-12-07 AT AT01270546T patent/ATE329614T1/en active
- 2001-12-07 ES ES01270546T patent/ES2266093T3/en not_active Expired - Lifetime
- 2001-12-07 CN CN200910163553A patent/CN101676299A/en active Pending
- 2001-12-07 SK SK706-2003A patent/SK7062003A3/en unknown
-
2003
- 2003-06-09 IL IL156360A patent/IL156360A/en not_active IP Right Cessation
- 2003-06-09 BG BG107891A patent/BG107891A/en unknown
- 2003-06-11 US US10/459,030 patent/US7271144B2/en not_active Expired - Fee Related
- 2003-06-12 NO NO20032656A patent/NO330767B1/en not_active IP Right Cessation
- 2003-07-10 HR HR20030564A patent/HRP20030564A2/en not_active Application Discontinuation
-
2004
- 2004-06-11 ZA ZA200304545A patent/ZA200304545B/en unknown
-
2006
- 2006-04-13 HK HK06104567.9A patent/HK1084400A1/en not_active IP Right Cessation
- 2006-06-27 CY CY20061100876T patent/CY1106108T1/en unknown
- 2006-10-03 US US11/542,050 patent/US7494973B2/en not_active Expired - Lifetime
-
2007
- 2007-09-06 US US11/899,611 patent/US7811985B2/en not_active Expired - Fee Related
-
2008
- 2008-10-09 US US12/248,656 patent/US8067373B2/en not_active Expired - Fee Related
-
2009
- 2009-05-29 CY CY20091100574T patent/CY1109107T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1084400A1 (en) | Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament | |
| EP0664786B1 (en) | Arginine keto-amide enzyme inhibitors | |
| EP0656008B1 (en) | Thrombin receptor antagonists | |
| AU601801B2 (en) | Anticoagulant peptides | |
| HU211158A9 (en) | Novel inhibitors of thrombin | |
| JPH09512022A (en) | Methionine sulfone and S-substituted cysteine sulfone derivatives as enzyme inhibitors | |
| PT95582B (en) | METHOD FOR PREPARING ANTAGONISTIC PEPTIDIC COMPOUNDS OF THE FIBRINOGENIC RECEPTOR | |
| JPH03118331A (en) | Cyclic fibrinogen receptor antagonist | |
| US6143719A (en) | Bradykinin analogs as selective thrombin inhibitors | |
| CA2122912A1 (en) | Novel peptides, and platelet aggregation-inhibiting agents, blood coagulation-inhibiting agents for extracorporeal circulation, cell adhesion-inhibiting agents, tumor metastasis inhibiting agents, agents for protecting platelet preparations for blood transfusion and platelet preparation packs for transfusion using said novel peptides | |
| WO1992007870A1 (en) | Platelet aggregation inhibitors | |
| AU641215B2 (en) | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin | |
| CA2168964C (en) | Novel peptide, and platelet aggregation-inhibiting agents, blood coagul ation-inhibiting agents for extracorporeal circulation, cell adhesion-inhibiting agents, tumor metastasis-inhibiting agents, agents for protecting platelet preparations for blood transfusion, platelet preparations and platelet preparation packs for transfusion using said novel peptides | |
| AU630132B2 (en) | Anticoagulant peptides | |
| EP0702696B1 (en) | Trifunctional antithrombin and antiplatelet peptides | |
| US5789540A (en) | Anticoagulant peptides | |
| AU2002331654B2 (en) | Peptide arginals and methods for treating disseminated intravascular coagulation | |
| EP0326013A3 (en) | Novel proteins derived from human alpha2-plasmin inhibitor or proteins similar thereto |